

FTO Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6976a**Specification**

FTO Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [O9C0B1](#)**FTO Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 79068

Other Names

Alpha-ketoglutarate-dependent dioxygenase FTO, 11411-, Fat mass and obesity-associated protein, FTO, KIAA1752

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6976a](/products/AP6976a) was selected from the N-term region of human FTO. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FTO Antibody (N-term) Blocking Peptide - Protein Information

Name FTO {ECO:0000303|PubMed:17496892, ECO:0000312|HGNC:HGNC:24678}

Function

RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis (PubMed: [22002720](http://www.uniprot.org/citations/22002720), PubMed: [26458103](http://www.uniprot.org/citations/26458103), PubMed: [28002401](http://www.uniprot.org/citations/28002401), PubMed: [30197295](http://www.uniprot.org/citations/30197295), PubMed: [26457839](http://www.uniprot.org/citations/26457839), PubMed: [25452335](http://www.uniprot.org/citations/25452335)). Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed: [22002720](http://www.uniprot.org/citations/22002720), PubMed: [22002720](http://www.uniprot.org/citations/22002720)).

<http://www.uniprot.org/citations/26458103> target="_blank">26458103, PubMed:30197295, PubMed:26457839, PubMed:25452335). M6A demethylation by FTO affects mRNA expression and stability (PubMed:30197295). Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295). Mediates demethylation of N(6),2'-O- dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295). Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed:28002401). Also acts as a tRNA demethylase by removing N(1)-methyladenine from various tRNAs (PubMed:30197295). Has no activity towards 1-methylguanine (PubMed:20376003). Has no detectable activity towards double-stranded DNA (PubMed:20376003). Also able to repair alkylated DNA and RNA by oxidative demethylation: demethylates single-stranded RNA containing 3-methyluracil, single- stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed:18775698, PubMed:20376003). Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed:18775698, PubMed:20376003). Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed:18775698, PubMed:20376003). Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed:26287746). Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity). Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed:28017614, PubMed:29249359).

Cellular Location

Nucleus. Nucleus speckle. Cytoplasm Note=Localizes mainly in the nucleus, where it is able to demethylate N(6)-methyladenosine (m6A) and N(6),2'-O-dimethyladenosine cap (m6A(m)) in U6 small nuclear RNA (snRNA), N(1)-methyladenine from tRNAs and internal m6A in mRNAs (PubMed:30197295). In the cytoplasm, mediates demethylation of m6A and m6A(m) in mRNAs and N(1)-methyladenine from tRNAs (PubMed:30197295).

Tissue Location

Ubiquitously expressed, with relatively high expression in adrenal glands and brain; especially in hypothalamus and pituitary (PubMed:17434869, PubMed:17496892). Highly expressed in highly expressed in acute myeloid leukemias (AML) with t(11;11)(q23;23) with KMT2A/MLL1 rearrangements, t(15;17)(q21;q21)/PML-RARA, FLT3-ITD, and/or NPM1 mutations (PubMed:28017614).

FTO Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

FTO Antibody (N-term) Blocking Peptide - Images**FTO Antibody (N-term) Blocking Peptide - Background**

The precise function of FTO remains to be determined.

FTO Antibody (N-term) Blocking Peptide - References

Scott,L.J., et.al., Science 316 (5829), 1341-1345 (2007)